Benzoimidazole compounds and uses thereof
View Patent ↗This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.
1. A compound of Formula I or a salt thereof, wherein the compound of Formula I corresponds to:
2. A compound or salt thereof according to claim 1 , wherein the compound corresponds to Formula II:
3. A compound or salt thereof according to claim 1 , wherein the compound corresponds to Formula III:
4. A pharmaceutical composition, wherein the composition comprises:
a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and
a carrier, diluent, or excipient.
5. A kit, wherein the kit comprises:
a compound or salt according to claim 1 ; and
an apparatus for administering the compound or salt to an animal patient;
instructions for administering the compound or salt to an animal patient; a carrier, diluent, or excipient; or a pharmaceutically active ingredient other than the compound or salt.
6. A method of inhibiting P2X3 activity for the treatment of a disorder associated with P2X3 activity in an animal in need of such treatment, wherein the method comprises administering to the animal a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
7. A method for treating pain in an animal in need of such treatment, wherein the method comprises administering to the animal a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
8. A method for treating a urinary tract disorder in an animal in need of such treatment, wherein the method comprises administering to the animal a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
9. A method according to claim 8 , wherein the urinary tract disorder comprises an overactive bladder.
10. A method according to claim 6 , wherein the animal is a human.
11. A method according to claim 7 , wherein the animal is a human.
12. A pharmaceutical composition, wherein the composition comprises:
a compound according to claim 2 or a pharmaceutically acceptable salt thereof; and
a carrier, diluent, or excipient.
13. A pharmaceutical composition, wherein the composition comprises:
a compound according to claim 3 or a pharmaceutically acceptable salt thereof; and
a carrier, diluent, or excipient.
14. A method of inhibiting P2X3 activity for the treatment of a disorder associated with P2X3 activity in an animal in need of such treatment, wherein the method comprises administering to the animal a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt thereof.
15. A method according to claim 14 , wherein the animal is a human.
16. A method for treating pain in an animal in need of such treatment, wherein the method comprises administering to the animal a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt thereof.
17. A method according to claim 16 , wherein the animal is a human.
18. A method for treating a urinary tract disorder in an animal in need of such treatment, wherein the method comprises administering to the animal a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt thereof.
19. A method according to claim 18 , wherein the animal is a human.
20. A method according to claim 18 , wherein the urinary tract disorder comprises an overactive bladder.
21. A method according to claim 20 , wherein the animal is a human.
22. A method of inhibiting P2X3 activity in the treatment of a disorder associated with P2X3 activity in an animal in need of such treatment, wherein the method comprises administering to the animal a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt thereof.
23. A method according to claim 22 , wherein the animal is a human.
24. A method for treating pain in an animal in need of such treatment, wherein the method comprises administering to the animal a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt thereof.
25. A method according to claim 24 , wherein the animal is a human.
26. A method for treating a urinary tract disorder in an animal in need of such treatment, wherein the method comprises administering to the animal a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt thereof.
27. A method according to claim 26 , wherein the animal is a human.
28. A method according to claim 27 , wherein the urinary tract disorder comprises an overactive bladder.
29. A method according to claim 28 , wherein the animal is a human.